MediWound (MDWD) H.C. Wainwright 27th Annual Global Investment Conference summary

Business strategy and product differentiation

• Enzymatic debridement technology validated in 14 clinical trials, with first product approved by FDA and EMA in over 40 countries.

• Technology replaces surgery for severe burns, offering eschar removal in four hours.

• Current focus on pivotal phase 3 study for venous leg ulcers, targeting a $2.5 billion market.

• Collaborations with major industry players enhance reach and credibility.

• Aim to assist as many patients as possible with innovative wound care solutions.

Key catalysts and clinical development

• Three major catalysts: BARDA RFP, completion of new manufacturing facility, and interim phase 3 study results.

• Operational activities for new facility to finish by year-end, regulatory approval to follow.

• Interim phase 3 results expected by mid-2026, determining potential $700 million peak sales.

• VLU phase 3 study is the largest in decades, with multiple global collaborators.

• Interim analysis at 65% enrollment to assess probability of success and adjust patient numbers if needed.

Partnerships and manufacturing expansion

• Collaborations with Solventum, Mölnlycke, MiMedx, and Essity for comprehensive trial support.

• Seven of the largest wound care companies involved in trials, aiming to set new standard of care.

• Manufacturing expansion includes new facilities in Israel and planned U.S. site, supported by BARDA funding.

• Flexibility to manufacture both EscharEx and NexoBrid across three facilities.

• U.S. and Israeli markets prioritized for NexoBrid supply; European and Asian markets face shortages until new facility approval.